SERA
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Sera Prognostics, Inc. (SERA) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Value (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | F (0.0) | B+ (3.6) | D+ (1.8) | B- (3.1) | C+ (2.6) | C (2.2) |
| 2026-11-07 | F (0.0) | B (3.4) | D+ (1.8) | B- (3.1) | C+ (2.7) | C (2.2) |
| 2026-10-31 | F (0.0) | B (3.3) | C- (1.9) | C+ (2.7) | C+ (2.7) | C- (2.1) |
| 2026-10-24 | F (0.0) | B (3.3) | C- (1.9) | C+ (2.6) | C+ (2.6) | C- (2.1) |
| 2026-10-17 | F (0.0) | B (3.3) | C- (1.9) | C (2.4) | C+ (2.6) | C- (2.0) |